首页> 外文期刊>European Heart Journal: The Journal of the European Society of Cardiology >Predicting survival after ECMO for refractory cardiogenic shock: The survival after veno-arterial-ECMO (SAVE)-score
【24h】

Predicting survival after ECMO for refractory cardiogenic shock: The survival after veno-arterial-ECMO (SAVE)-score

机译:预测难治性心源性休克ECMO后的存活率:静脉动脉ECMO(SAVE)评分后的存活率

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Rationale Extracorporeal membrane oxygenation (ECMO) may provide mechanical pulmonary and circulatory support for patients with cardiogenic shock refractory to conventional medical therapy. Prediction of survival in these patients may assist in management of these patients and comparison of results from different centers. Aims To identify pre-ECMO factors which predict survival from refractory cardiogenic shock requiring ECMO and create the survival after veno-arterial-ECMO (SAVE)-score. Methods and results Patients with refractory cardiogenic shock treated with veno-arterial ECMO between January 2003 and December 2013 were extracted from the international Extracorporeal Life Support Organization registry. Multivariable logistic regression was performed using bootstrapping methodology with internal and external validation to identify factors independently associated with in-hospital survival. Of 3846 patients with cardiogenic shock treated with ECMO, 1601 (42%) patients were alive at hospital discharge. Chronic renal failure, longer duration of ventilation prior to ECMO initiation, pre-ECMO organ failures, pre-ECMO cardiac arrest, congenital heart disease, lower pulse pressure, and lower serum bicarbonate (HCO3) were risk factors associated with mortality. Younger age, lower weight, acute myocarditis, heart transplant, refractory ventricular tachycardia or fibrillation, higher diastolic blood pressure, and lower peak inspiratory pressure were protective. The SAVE-score (area under the receiver operating characteristics [ROC] curve [AUROC] 0.68 [95%CI 0.64-0.71]) was created. External validation of the SAVE-score in an Australian population of 161 patients showed excellent discrimination with AUROC = 0.90 (95%CI 0.85-0.95). Conclusions The SAVE-score may be a tool to predict survival for patients receiving ECMO for refractory cardiogenic shock (www.save-score.com).
机译:原理体外膜氧合(ECMO)可以为传统医学疗法难以治疗的心源性休克患者提供机械肺和循环支持。预测这些患者的存活率可能有助于管理这些患者并比较不同中心的结果。目的确定ECMO前因子,这些因子可预测需要ECMO的难治性心源性休克的存活率,并在静脉-动脉ECMO(SAVE)评分后创建存活率。方法和结果2003年1月至2013年12月期间接受静脉动脉ECMO治疗的难治性心源性休克患者摘自国际体外生命支持组织注册表。使用内部和外部验证的自举方法进行多变量logistic回归,以识别与医院生存独立相关的因素。在3846名接受ECMO治疗的心源性休克患者中,有1601名(42%)患者在出院时还活着。慢性肾功能衰竭,开始ECMO之前通气时间延长,ECMO之前的器官衰竭,ECMO之前的心脏骤停,先天性心脏病,较低的脉压和较低的碳酸氢盐(HCO 3 )是有风险的与死亡率有关的因素。年龄较小,体重较轻,急性心肌炎,心脏移植,难治性室性心动过速或纤颤,舒张压升高和吸气峰压降低是有保护作用的。创建了SAVE得分(接收器工作特性[ROC]曲线[AUROC] 0.68 [95%CI 0.64-0.71]下的区域)。在澳大利亚161例患者中,对SAVE评分的外部验证显示出极好的区分性,AUROC = 0.90(95%CI 0.85-0.95)。结论SAVE评分可能是预测接受ECMO难治性心源性休克患者生存率的工具(www.save-score.com)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号